On September 23, PHARMARON rose 4.16% in regular trading, trading at HK$31.38/share, with turnover of approximately HK$52.17 million. The rally was driven by sustained strength across the CRO sector combined with bullish signals from multiple global investment banks.
On the institutional front, Goldman Sachs reiterated a Buy rating on PHARMARON, while Daiwa, Bank of America, and Morgan Stanley raised their target prices to HK$38.5, HK$38.4, and HK$35.6, respectively — all implying significant upside from the current trading level. JPMorgan previously increased its H-share stake to 17.16%, and Morgan Stanley also added to its position, reflecting continued foreign institutional accumulation.
Additionally, the company's controlling shareholder's concert party, Ningbo Longtaikang, released a pledge on 2.17 million shares on September 21, a move generally viewed as a positive signal regarding insider financial health. The broader CRO sector has benefited from multiple tailwinds, including a landmark AI-driven drug development collaboration between Novo Nordisk and Anthropic, domestic innovative drug licensing deals surpassing US$120 billion, and recent supportive policy measures from ten government departments.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments